Skip to main content
. 2013 Apr 18;7(4):e2181. doi: 10.1371/journal.pntd.0002181

Table 1. Antibody responses of mice vaccinated with MP-12 or the variants.

42 days post vaccination a-NSs IgG (OD405)
Virus Mouse # Protection PRNT80 a-N IgG Pre Post
MP-12 14-1 Dead (7 dpi) - 3,200 0.11 -
14-5 Dead (8 dpi) - 3,200 0.11 -
15-3 Dead (7 dpi) - 409,600 0.10 -
3-1 Dead (7 dpi) - 800 0.14 -
3-3 Dead (7 dpi) - - 0.12 -
3-5 Dead (13 dpi) - - 0.14 -
4-1 Dead (7 dpi) - - 0.12 -
14-4 Survived - 819,200 0.63* 0.74*
15-2 Survived - 1,638,400 0.12 0.29*
14-3 Survived - - 0.11 3.50*
14-2 Survived 2,560 12,800 0.13 1.15*
15-4 Survived 2,560 800 0.12 0.28*
15-5 Survived 2,560 1,638,400 0.38* 0.50*
3-2 Survived 640 409,600 0.12 0.42*
3-4 Survived 640 819,200 1.84* 1.74*
4-2 Survived 640 409,600 0.13 0.88*
4-3 Survived 640 204,800 0.09 1.05*
4-4 Survived 640 204,800 1.05* 1.08*
4-5 Survived 640 819,200 1.45* 1.86*
rMP12-PTNSs 16-2 Survived 2,560 6,400 0.13 0.25*
16-3 Survived 2,560 6,400 0.12 0.23*
16-4 Survived 160 25,600 0.11 0.27*
17-1 Survived 2,560 819,200 0.12 0.65*
17-2 Survived 640 102,400 0.11 0.22*
17-3 Survived 2,560 819,200 0.10 0.47*
17-4 Survived 2,560 204,800 0.12 0.25*
17-5 Dead (8 dpi) - 3,200 0.11 -
16-1 Dead (10 dpi) - 3,200 0.13 -
rMP12-SFSNSs 20-1 Survived 160 204,800 0.18 0.48*
20-2 Survived 640 819,200 0.14 0.66*
20-3 Survived 160 204,800 0.13 0.69*
20-4 Survived 640 409,600 0.13 0.58*
21-3 Survived 2,560 819,200 0.14 0.51*
21-4 Survived 640 819,200 0.11 0.42*
21-5 Survived - 204,800 0.15 1.19*
21-1 Survived - 102,400 0.15 0.76*
21-2 Dead (9 dpi) - 102,400 0.14 -
rMP12-NSsR173A 7-1 Survived 160 400 0.10 0.57*
7-4 Survived 10 800 0.13 0.14
8-1 Survived 10 6,400 0.15 0.54*
7-3 Survived - 6,400 0.12 0.44*
8-5 Survived - 800 0.13 1.20*
7-2 Dead (13 dpi) - 400 0.12 -
7-5 Dead (13 dpi) - 400 0.11 -
8-2 Dead (9 dpi) - 3,200 0.11 -
8-3 Dead (8 dpi) - - 0.10 -
8-4 Dead (11 dpi) - - 0.10 -
PBS 12-4 Survived - - 0.13 1.92*
*

a-NSs IgG positive (cut-off = 0.204).

Pre: 42 days post vaccination, Post: 21 days post wt RVFV challenge.